GlassScriptPhysician profile
Diane R Sharkey
NPI 1023549052
$1,261.46
in general payments reported to CMS, 2019-2025
21 companies · $135 in 2025
The $135 reported for 2025 was less than what a typical Family provider received nationally (typical 2025 total: $167).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $178 · 2022: $516 · 2023: $249 · 2024: $183 · 2025: $135.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $567.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $567.03 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Novartis Pharmaceuticals Corporation | $336.96 | 2021-2023 | |
| Boston Scientific Corporation | $184.35 | 2021-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $82.33 | 2022-2024 | Lifevest |
| Pfizer INC. | $74.65 | 2022-2025 | |
| Amgen INC. | $73.93 | 2022-2023 | Repatha |
| Merck Sharp & Dohme LLC | $61.50 | 2023-2025 | Verquvo, Capvaxive |
| Abbott Laboratories | $51.11 | 2022-2025 | Cardiomems |
| E.R. Squibb & Sons, L.L.C. | $41.54 | 2022-2024 | Camzyos |
| Kiniksa Pharmaceuticals International, Plc | $37.68 | 2024 | Arcalyst |
| Medtronic, INC. | $36.68 | 2021 | |
| Janssen Pharmaceuticals, INC | $33.17 | 2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $32.33 | 2021-2025 | Jardiance |
| United Therapeutics Corporation | $32.18 | 2023 | Tyvaso |
| Astrazeneca Pharmaceuticals LP | $29.96 | 2022-2023 | Andexxa |
| Chiesi USA, INC. | $28.89 | 2023 | Cleviprex, Kengreal |
Show all 21 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Alnylam Pharmaceuticals INC. | $26.57 | 2025 | Onpattro |
| Actelion Pharmaceuticals US, INC. | $26.09 | 2022-2024 | Opsumit, Uptravi |
| Regeneron Healthcare Solutions, INC. | $22.30 | 2025 | Evkeeza |
| W. L. Gore & Associates, INC. | $17.41 | 2024 | Gore Excluder Aaa Endoprosthesis |
| Scpharmaceuticals INC. | $16.53 | 2024 | |
| Bayer Healthcare Pharmaceuticals INC. | $15.30 | 2022 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Diane Sharkey listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.